Highest-materiality recent filing
Scilex sells Vivasor preferred shares for $12M; CEO Henry Ji on both sides
Scilex sells 6.1M Series A-1 and 355.9K Series A-2 Vivasor preferred shares for $12M ($1.8583/share).
Scilex signs binding term sheet for $100M investment from iHolding at $15/share
iHolding to purchase $100M of newly issued shares at $15/share (~6.67M shares).
Scilex signs binding term sheet to buy 837 Bitcoin from Datavault for $50M
Purchase of 837 BTC from Datavault AI Inc. for $50M; initial $30M cash payment due at closing.
Scilex subsidiary to sell ACEA Pharma to Phoenix Asia for $1B in stock, owning 82% post-close
ACEA Thera sells 100% of ACEA Pharma to Phoenix Asia for 100M shares at $10/share, valued at $1B.
Scilex to pay $120M to Datavault for quantum GPU network, revenue-sharing deal
Upfront cash contribution of $120M to Datavault, payable in multiple closings by Dec 31, 2026.
Complaint filed March 11, 2026, against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.
Scilex files federal securities fraud lawsuit over 96M misappropriated Datavault collateral shares
Filed complaint in Central District of California against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.
Scilex issues warrant to Oramed for 100,000 shares at $20.00 in exchange for payment deferral
Warrant for 100,000 shares at $20.00 issued to Oramed Pharmaceuticals for deferring an amortization payment originally due Oct 1, 2025.
Scilex loans $20M to Q Scan, converts to shares; agrees $27.5M stock purchase
Loaned $20M to Q Scan via convertible note; note converted same day into 140.4M Q Scan common shares.
Completed second tranche of warrant repurchase on Dec 30, 2025 for $14M, following $13M first tranche in Sep 2025.
Scilex subsidiary enters $100M non-recourse loan secured by SCLX pledge
Up to $100M in tranches at lender's sole discretion; interest at 12-month SOFR.
Scilex stockholders approve repricing of stock options from $282.80 to $16.80 per share
Stockholders approved repricing of up to 289,405 options held by employees, executives, and board members.
Scilex secures up to $50M non-recourse loan secured by 39.2M shares of Datavault AI (DVLT)
Loan of up to $50M in tranches at 12-month SOFR + 2.0% interest, maturity 4 years from first tranche.
Scilex completes $150M Bitcoin investment in Datavault AI, warrant shares now valued at $583M
Scilex purchased a pre-funded warrant for 263,914,094 Datavault shares in the second tranche, paying in Bitcoin.
Scilex receives $20.4M from Armistice warrant exercise; issues new warrants for 1.36M shares
Existing warrants (904,396 shares) exercised at reduced price $22.51/share, gross proceeds $20.36M.
Scilex in-licenses Datavault AI tech for biotech asset tokenization; $10M upfront, $2.55B milestones
Worldwide exclusive license from Datavault AI for tokenizing genomic, DNA, diagnostic, therapeutic data in biotech/pharma.
Scilex enters warrant exercise agreement for $2.7M proceeds; issues new warrants for 275K shares
Existing warrant holders exercise 179,236 shares at net $15.00/share after $7.72 deferral fee, raising ~$2.7M.
Scilex sells 12.5M Semnur shares for $200M Bitcoin; closes Sept 23, 2025
Scilex sold 12,500,000 Semnur common shares at $16.00/share to Biconomy for $200M in Bitcoin.
Scilex invested $150M in Bitcoin for Datavault AI (DVLT) shares and warrants at $0.5378 per share effective price.
Scilex CEO Jaisim Shah resigns to focus on Semnur; Henry Ji appointed CEO; Semnur gets $20M PIPE
Jaisim Shah resigned as CEO/President of Scilex effective Aug 17, 2025; remains on Board and will focus full time on Semnur.
Scilex enters $100M equity line, exchanges warrants, gets option to repurchase Penny Warrants
Equity line with Tumim Stone Capital: up to $100M common stock at 96-97% of lowest VWAP; 150k commitment shares.
Scilex subsidiary Semnur amends Denali merger deal to allow additional share issuances pre-closing
Amendment modifies Exchange Ratio and Merger Consideration definitions to account for shares issued after signing date (PIPE/Advisor Shares).
Amendment dated April 16, 2025 modifies covenants to address Denali's de-listing from Nasdaq and subsequent quotation on OTC Markets.
Scilex shareholders approve reverse stock split within 1:14 to 1:50 range
Shareholders approved reverse stock split of common stock at ratio between 1:14 and 1:50; board to set final ratio by March 19, 2026.
Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026
Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.
Scilex regains Nasdaq compliance by filing overdue Q3 2024 10-Q
Filed Form 10-Q for quarter ended Sept 30, 2024 on Jan 17, 2025, curing late filing.
Scilex defers $6.25M amortization payment, issues 5M shares to noteholders
Entered deferral letters with Tranche B noteholders; first $6.25M amortization due Jan 2 deferred to Jan 31, then to Oct 8, 2026.
Scilex raises $17M in registered direct offering, plus $1M warrant exercise
Gross proceeds ~$17M from sale of 26.355M shares, pre-funded warrants, and 57.513M common warrants.
On November 27, 2024, David Lemus notified the Board of Directors (the “ Board ”) of Scilex Holding Company (the “ Company ”) that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of November 27, 2024, for personal and professional reasons.
On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).
On September 21, 2023, Laura J. Hamill notified the Board of Directors (the “ Board ”) of the Company that she was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of September 21, 2023.
On September 20, 2023, Elizabeth Czerepak, the Executive Vice President, Chief Business Officer, Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer and Secretary of Scilex Holding Company (the “ Company ”), resigned from the Company, effective immediately.
On September 22, 2023, the Company appointed Stephen Ma, age 51, as the Company’s Chief Financial Officer, effective immediately.
On August 27, 2023, Tien-Li Lee, M.D. notified the Board of Directors (the “Board”) of the Company that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of August 27, 2023.
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 27, 2023, Dr. Ji notified the Board that he was resigning from his position as an executive officer of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
On August 27, 2023, Henry Ji, Ph.D. was informed that, pursuant to Article V.E. of the Company’s Restated Certificate of Incorporation, the chief restructuring officer on behalf of Sorrento in its pending bankruptcy proceedings, as the holder of a majority in voting power of the then-outstanding shares of stock of the Company entitled to vote generally in the election of directors, had taken action by written consent to remove Dr. Ji as a director of the Company, effective as of such date.
On August 27, 2023, Laura J. Hamill notified the Board that she was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company effective as of and contingent upon the closing of the Oramed Transaction.
On August 29, 2023, Jaisim Shah notified the Board that he was retiring from the Board, all committees of the Board, his position as the Chief Executive Officer and President of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
Max materiality 0.85 · Median 0.60 · Most common event other_material